- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Vital Images 3D Viewer Receives FDA Clearance
Vital Images Inc. announced the FDA has granted 510(k) clearance for 3D viewing through the VitreaView universal viewer.
Vital Images Inc., a Toshiba Medical Systems Group company, has received FDA 510(k) clearance for 3D viewing through the VitreaView universal viewer, the company announced.
The advanced visualization and analysis company introduced VitreaView in June 2011. The viewer is used as a communication tool for DICOM and non-DICOM medical images through a standardized viewer, so clinicians can access the images through various systems.
“Now with 3D and tablet capabilities available via VitreaView, our customers, particularly referring physicians and clinicians, have more functionality and easier access to the tools they need,” Erkan Akyuz, president and CEO of Vital Images, said in a statement. “Also, with access to images through the EMR as part of the Stage 2 Meaningful Use criteria, VitreaView integrated with a certified EMR enables the ability to meet this objective, with a toolset and infrastructure that also meets the needs of clinical users and IT administrators.”
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
